Is NAD+ therapy safe for weight loss
Lack of Human Clinical Data The most significant limitation is the near-complete absence of published human clinical trial data: No peer-reviewed human efficacy trials exist in scientific literature as of 2025 One analog compound (CB4211) completed Phase 1 safety testing, but results not published in peer-reviewed journals Human optimal dosing, safety profile, and efficacy completely unestablished Long-term effects of exogenous MOTS-c administration in humans unknown No published data on human absorption, distribution, metabolism, or excretion While endogenous MOTS-c levels have been measured in human populations and exercise studies confirm its physiological presence, therapeutic use remains entirely experimental
(PubMed) de Menezes Barbosa EG, Junior FB, Machado AA, Navarro AM
doi: 10.1111/dom.12674 27 AhrnBHirschIBPieberTRMathieuCGmez-PeraltaFHansenTKet al
The front and outer thigh provide the largest surface area for rotation
Gofrit ON, Bercovier H, Klein BY, Cohen IR, Ben-Hur T, Greenblatt CL